A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).

Trial Details

NCT ID
NCT07705334
Phase
PHASE1
Sponsor
SHY Therapeutics
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • SHY-ONC6
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Denver, Colorado, United States|39.73915,-104.9847
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Male or female ≥18 years of age.
  • Life expectancy \>3 months.
  • ECOG performance status 0-1.
  • Histologically/cytologically confirmed advanced or metastatic solid tumors that have progressed on or are intolerant/unsuitable for standard therap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →